Objectives. 3-year research data on transendocardial implantation of autologous bone marrow mononuclear cells (ABMMC) in CAD patients with a preserved systolic function of the left ventricle (LV) were analyzed. Methods. The study included 30 patients with post-infarction cardiosclerosis, with their LV EF varying from 50 % to 70 %. To administer an average 41 16 x 10 ⁶ dose of ABMMC into the myocardial infarction borderline, the NOGA system was used. Results. Lethality at 36 months was 6.6 % (2 patients) and both cases were not related to the main pathology. Within 36 months of ABMMC implantation, the functional class of angina improved from с 2.80.1 to 2.1 01 (р<0.05) and NYHA functional class decreased from 2.80.1 to 2.30.1 (p<0.05). After 36 postoperative months, in most patients the cumulative myocardial perfusion observed at 12 months remained the same in the ABMMC segments. Transendocardial implantation is a safe intervention that improves patients hemodynamic parameters and quality of life.